Intravenous thrombolysis with recombinant tissue plasminogen activator is considered the standard of care in patients with acute ischemic stroke presenting within 4.5 h after onset. Neuroimaging ...

In March, the FDA approved one-time, 5-second IV bolus tenecteplase (TNKase, Genentech) for the treatment of acute ischemic stroke in adults. As Healio previously reported, tenecteplase is the ...

Imperative Care announced that it intends to fund a trial comparing its Zoom stroke system plus best medical treatment to ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ischemic stroke have been granted approval by the US Food and Drug ...

DiaMedica Therapeutics progresses DM199 for ischemic stroke and preeclampsia, aiming to expand treatment windows. Read why ...

The effects and risks of the use of intravenous thrombolysis between 4.5 and 24 hours after the onset of a posterior circulation ischemic stroke are not well studied. In a trial conducted in China ...

Imperative Care, Inc. announced it will fund an investigator-initiated, multicenter, randomized controlled clinical trial compari ...

Imperative Care, Inc. will fund an independent, randomized clinical trial for the treatment of M2 occlusions in stroke patients.

Understanding and categorizing the various types of tubulointerstitial responses in acute kidney injury (AKI) may lead to the ...

Anaconda Biomed, SL, announced the publication of results of the ANAIS study, which evaluated the safety and performance of the c ...